Aug 2026· Obesity Surgery· Vol 36, pp. 5145 - 5153· 0 citations· 29 references
Medicine
TL;DR
These findings provide preliminary reference points that require prospective validation before being considered for clinical guidance and show consistency across age, preoperative BMI, and type 2 diabetes mellitus subgroups in this cohort.
While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight reductio...
E. G. Manueli Laos, Andres Fontaine-Nicola, Bianca Serafica et al.· Clinical Obesity· 0 citations
BACKGROUND
Although laparoscopic sleeve gastrectomy (LSG) is an effective treatment for severe obesity, some patients experience suboptimal weight loss or an early weight-loss plateau during postoperative follow-up. Semaglutide has emerged as an effective pharmacological option for obesity management; however, evidence...
Pamela Jeske, Julia Roleder, Kinga Zastawna et al.· Surgical Endoscopy· 0 citations
Greater weight loss after MBS is associated with more pronounced metabolic benefits, yet preoperative characteristics do not distinguish between trajectory groups, underscoring the heterogeneity in surgical response and the need for further research into the determinants of differential outcomes.
Lei Zhang, Xi-Han Li, Shi-Yan Zhang et al.· Obesity Surgery· 0 citations
Food craving (FC) is an established predictor of obesity. However, its role in weight management is insufficiently addressed in routine clinical practice.
This retrospective study included adults with obesity, stratified by FC status, to compare the effectiveness of semaglutide plus hypocaloric diet (semaglu...
Simona Bertoli, F. Barbera, C. Cappellini et al.· Frontiers in Endocrinology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.